Advertisement
"Our global corporate deployment capabilities are at the heart of our AEDsales strategy. These recent wins demonstrate our continued success in thisarea," said John Hinson, Cardiac Science president and chief executiveofficer.
Advertisement
Fifteen minutes after a Cummins Engine employee learned how to use aPowerheart AED, he saved a colleague's life.
"There is a real need for accessible defibrillation in the workplace,"added Mr. Hinson. "According to the Occupational Safety & HealthAdministration, 15% of all workplace fatalities are sudden cardiac arrests.That we were able to play such a vital role in a life saving event so soonafter deployment underscores the value and importance of the products andservices we provide. We applaud Cummins and CH2M HILL for their commitment tocreating heart safe environments at their locations worldwide."
Cardiac Science's global program management services help customers complywith applicable regulatory requirements and practical logistics issuesconcerning AED placement and usage. This includes American Heart Associationcertified training, meticulous record keeping, and a licensed physician tooversee the program.
About Cardiac Science Corporation
Cardiac Science develops, manufactures, and markets a family of advanceddiagnostic and therapeutic cardiology devices and systems, including AEDs,electrocardiographs, stress test systems, Holter monitoring systems, hospitaldefibrillators, cardiac rehabilitation telemetry systems, and cardiology datamanagement systems (informatics) that connect with hospital information (HIS),electronic medical record (EMR), and other systems. The Company sells avariety of related products and consumables, and provides a portfolio oftraining, maintenance, and support services. Cardiac Science, the successorto the cardiac businesses that established the trusted Burdick(R),Powerheart(R), Quinton(R), and HeartCentrix(R) brands, is headquartered inBothell, Washington. With customers in more than 100 countries worldwide, thecompany has operations in the North America, Europe, and Asia. Forinformation, call 425-402-2000 or visit http://www.cardiacscience.com.
Forward-Looking Statements
This press release contains forward-looking statements including, but notlimited to, those that infer that Cardiac Science Corporation's future revenueand profits may grow as a result of sales of defibrillation products. Thesestatements and their underlying assumptions involve a number of risks anduncertainties and are not guarantees of future performance. These areforward-looking statements for purposes of the safe harbor provisions underthe Private Securities Litigation Reform Act of 1995. The words "believe,""expect," "intend," anticipate," variations of such words, and similarexpressions identify forward-looking statements, but their absence does notmean that the statement is not forward looking. Actual results may varysignificantly from the results expressed or implied in such statements.Factors that could cause or contribute to such varying results and other risksare more fully described in the Annual Report on Form 10-K filed by CardiacScience Corporation for the year ended December 31, 2006. Cardiac ScienceCorporation undertakes no duty or obligation to update the informationprovided herein.(Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO) The recent Cardiac Science deals are with the following companies: -- CH2M HI
